Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis

por Anderson, Evan, Jackson, Lisa, Rouphael, Nadine, Widge, Alicia, Montefiori, David, Doria-Rose, Nicole, Suthar, Mehul, Cohen, Kristen, O’Connell, Sarah, Makowski, Mat, Makhene, Mamodikoe, Buchanan, Wendy, Spearman, Paul, Creech, C. Buddy, O’Dell, Sijy, Schmidt, Stephen, Leav, Brett, Bennett, Hamilton, Pajon, Rolando, Posavad, Christine, Hural, John, Beigel, John, Albert, Jim, Abebe, Kuleni, Eaton, Amanda, Rostad, Christina, Rebolledo, Paulina, Kamidani, Satoshi, Graciaa, Daniel, Coler, Rhea, McDermott, Adrian, Ledgerwood, Julie, Mascola, John, DeRosa, Stephen, Neuzil, Kathleen, McElrath, M. Juliana, Roberts, Paul
Publicado 2022

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

por Branche, Angela, Rouphael, Nadine, Diemert, David, Falsey, Ann, Losada, Cecilia, Baden, Lindsey (R), Frey, Sharon, Whitaker, Jennifer, Little, Susan, Anderson, Evan, Walter, Emmanuel, Novak, Richard, Rupp, Richard, Jackson, Lisa, Babu, Tara, Kottkamp, Angelica, Luetkemeyer, Annie, Immergluck, Lilly, Presti, Rachel, Backer, Martin, Winokur, Patricia, Mahgoub, Siham, Goepfert, Paul, Fusco, Dahlene, Malkin, Elissa, Bethony, Jeff, Walsh, Edward, Graciaa, Daniel, Samaha, Hady, Sherman, Amy, Walsh, Stephen, Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana, Martin, Thomas, Kamidani, Satoshi, Smith, Michael, Ladner, Benjamin, Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert, Mulligan, Mark, Lyke, Kirsten, Posavad, Christine, Meagher, Megan, Stephens, David, Neuzil, Kathleen, Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri, Giebeig, Lisa, Eaton, Amanda, Netzl, Antonia, Wilks, Sam, Tureli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David, Makowski, Mat, Smith, Derek, Nayak, Seema, Roberts, Paul, Beigel, John
Publicado 2023

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

por Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C. S., Kamidani, Satoshi, Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David C., Makowski, Mat, Smith, Derek J., Nayak, Seema U., Roberts, Paul C., Beigel, John H.
Publicado 2023